Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients: A Systematic Review

Abstract

Background: Hemorrhagic and thromboembolic complications are common during treatment with extracorporeal membrane oxygenation (ECMO), resulting in considerable morbidity and mortality. This emphasizes the clinical relevance of understanding hemostatic changes occurring during ECMO treatment. As platelets are key players in hemostasis, detailed knowledge on how ECMO treatment affects platelet function is of great importance. We therefore aimed to systematically summarize and discuss existing knowledge on platelet function during ECMO treatment in adult patients.Methods: Systematic review complying with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Objectives and methods were specified in a PROSPERO protocol (ID no CRD42018084059). The MEDLINE/PubMed, EMBASE, and Web of Science databases were systematically searched on September 10, 2018. A standardized quality assessment tool was used to assess the risk of bias in included studies. Primary outcome was platelet function during ECMO treatment, measured as platelet adhesion, activation or aggregation. Secondary outcomes were thrombosis, bleeding, and mortality during ECMO treatment.Results: A total of 591 studies were identified, of which seven were eligible for inclusion in the qualitative synthesis. Of these, one study investigated expression of platelet adhesion receptors and found them to be reduced during ECMO treatment; two studies reported a decrease in platelet activation markers during ECMO treatment; and five studies demonstrated reduced platelet aggregation during ECMO treatment. Three studies reported on thrombosis, mortality and/or bleeding during ECMO treatment; no thromboembolic events were reported; all three studies reported frequent bleeding episodes defined on basis of transfusion requirements. An in-hospital mortality of 35–40% and a 30-day mortality of roughly 30% were reported in three different studies.Conclusions: The present systematic review reveals a substantial knowledge gap regarding platelet function during ECMO treatment in adult patients and underscores the demand for more and well-designed studies on this topic. There is suggested evidence of reduced platelet adhesion, decreased platelet activation, and reduced platelet aggregation in adult patients during ECMO treatment. Importantly, platelet aggregation results need to be interpreted in the light of low platelet counts. The associations of platelet function and bleeding and/or thromboembolic complications during ECMO treatment remain to be fully elucidated.

Platelet Functions During Extracorporeal Membrane Oxygenation. Platelet–Leukocyte Aggregates Analyzed by Flow Cytometry as a Promising Tool to Monitor Platelet Activation

“…In a systematic recent review, Balle et al reported that there are only a limited number of published studies investigating platelet functions in patients during ECMO therapy. These studies suggest a reduced potential for platelet adhesion, activation, and aggregation during ECMO [7].…”

COVID-19 and ECMO: the interplay between coagulation and inflammation—a narrative review

“…It is widely acknowledged that the majority of COVID-19 patients, especially those with severe disease, are characterized by lymphocytopenia. This laboratory symptom is observed mostly in adult patients, much less often to children [45], and may predict COVID-19 severity [53]. The second important remark is that the reduced number of lymphocytes is also a common feature of diseases caused by other coronaviruses, including SARS [54] and MERS [55].…”

Sources of human infection by Salmonella enterica serotype Javiana: A systematic review

“…For the studies included in this systematic review, a thorough assessment of the methodological quality and risk of bias analysis was performed by two authors (NM and PB) independently. The Newcastle-Ottawa Scale (NOS) was used for case-control studies [28, 29], while the case series studies were appraised using National Heart, Lung, and Blood Institute (NHLBI) Study Quality Assessment Tools [30, 31]. NOS for case-control studies included three criteria 1) Selection (which was evaluated based on a) if the case definition was adequate, b) representativeness of the cases, c) selection of controls and d) definition of controls; 2) Comparability (evaluated based on the comparability of case and controls in terms of study design and data analysis); 3) Exposure (assessed by a) ascertainment of exposure, b) whether or not the same method of ascertainment was applied for cases and controls, and c) non-response rate).…”